Role of cell-free DNA for predicting incidence and outcome of patients with ischemic stroke

Table 2 The tabulation of the different stroke conditions of cell-free DNA assessment

	Ref.	Disease specification	Source	Nucleic acid type	Outcome of the study
1	Tsai et al[29], 2011	Acute ischemic stroke	Plasma	cfDNA	Elevated plasma cf-nuclear and mitochondrial DNA in acute ischemic stroke patients than healthy controls
2	O’Connell et al[34], 2017	Ischemic stroke	Plasma	cfDNA	Elevated cfDNA in stroke patients relative to those diagnosed as stroke mimics (P = 0.001)
3	Naumann et al[28], 2017	Acute ischemic stroke	Plasma	cfDNA	IVT was associated with improved outcome in patients with cfDNA < 10000 kilogenome-equivalents/L (P < 0.05)
4	Vajpeyee et al[30], 2018	Acute ischemic stroke	Plasma		Higher cfDNA levels were associated with severity at the time of admission (P = 0.003) and poor outcome as measured by modified Rankin scale 3-mo scores (P = 0.001). Therapeutic intervention mechanical thrombectomy or IV thrombolysis associated with improved outcome in patients with cfDNA < 10000 kilogenome equivalents/L (P ≤ 0.01)
5	Kananen et al[36], 2020	Mortality rate	Plasma	cfDNA	cfDNA associated with increased risk of mortality (hazard ratio 0.1 μg increase in cfDNA, P = 0.0003)

cfDNA: Cell-free DNA.